This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Mar 20;36(9):908-910.

doi: 10.1200/JCO.2017.77.5254. Epub 2018 Jan 31.

HIF2 Inhibitor Joins the Kidney Cancer Armamentarium

William G Kaelin Jr¹

Affiliations

PMID: 29384723
DOI: 10.1200/JCO.2017.77.5254

Comment

HIF2 Inhibitor Joins the Kidney Cancer Armamentarium

William G Kaelin Jr. J Clin Oncol. 2018.

. 2018 Mar 20;36(9):908-910.

doi: 10.1200/JCO.2017.77.5254. Epub 2018 Jan 31.

Author

William G Kaelin Jr¹

Affiliation

¹ William G. Kaelin Jr, Harvard Medical School, Boston, MA.

PMID: 29384723
DOI: 10.1200/JCO.2017.77.5254

No abstract available

PubMed Disclaimer

Comment on

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK. Courtney KD, et al. J Clin Oncol. 2018 Mar 20;36(9):867-874. doi: 10.1200/JCO.2017.74.2627. Epub 2017 Dec 19. J Clin Oncol. 2018. PMID: 29257710 Free PMC article. Clinical Trial.

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information